Characteristics | N = 56 | % |
---|---|---|
Age, years | ||
 Median | 55.5 |  |
 Range | 23–74 |  |
  < 55 years | 25 | 44.6 |
  ≥ 55 years | 31 | 55.4 |
Menopausal status | ||
 Premenopausal a | 14 | 25.0 |
 Postmenopausal | 42 | 75.0 |
Disease-free interval b | ||
  > 5 y | 31 | 55.4 |
  ≤ 5 y | 22 | 39.3 |
Histology of primary breast cancer | ||
 IDC | 49 | 87.5 |
 ILC | 7 | 12.5 |
Hormone-receptor status | ||
 ER-positive and PR-positive | 46 | 82.1 |
 ER-positive and PR-negative | 10 | 17.9 |
Metastatic sites | ||
 Nonvisceral | 30 | 53.6 |
 Bone | 37 | 66.1 |
  Bone-only | 12 | 21.4 |
  Visceral disease | 26 | 46.4 |
  Any lung | 13 | 23.2 |
  Pleural | 7 | 12.5 |
  Peritoneum | 1 | 1.8 |
   Ovarian | 2 | 3.6 |
   Liver | 6 | 7.0 |
No. of disease sites | ||
 1 | 18 | 32.1 |
 2 | 20 | 35.8 |
  ≥ 3 | 18 | 32.1 |
De novo metastatic disease | 3 | 5.4 |
Lines of therapy prior to palbociclib | ||
 0 | 38 | 67.9 |
 1 | 9 | 16.1 |
 2 | 4 | 7.1 |
  ≥ 3 | 5 | 8.9 |
Prior ET for metastatic disease | ||
 None | 43 | 76.8 |
 Yes | 13 | 23.2 |
Prior ET type for metastatic disease | ||
 Antiestrogen ± LH-RH analog | 8 | 14.3 |
 Aromatase inhibitor ± LH-RH analog | 9 | 16.1 |
Prior chemotherapy for metastatic disease | ||
 None | 43 | 76.8 |
 Yes | 13 | 23.2 |
Endocrine therapy following FES PET | ||
 palbociclib + Aromatase inhibitor | 19 | 33.9 |
 palbociclib + fulvestrant | 37 | 66.1 |
Outcome | ||
 CR | 3 | 5.4 |
 PR | 6 | 10.7 |
 SD | 34 | 60.7 |
 PD | 13 | 23.2 |
Clinical benefit | ||
 None | 13 | 23.2 |
 Yes | 43 | 76.8 |
PFS | ||
 Events | 34 | 60.7 |
 Censored | 22 | 39.3 |
With negative 18F-FES lesions | ||
 None | 46 | 82.1 |
 Yes | 10 | 17.9 |